Evaluating the effect of rapamycin treatment in Alzheimer’s disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol

Evaluating the effect of rapamycin treatment in Alzheimer’s disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol

Abstract Background Rapamycin is an inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, and preclinical data demonstrate that it is a promising candidate for a general gero- and neuroprotective treatment in humans. Results from mouse models of Alzheimer’s disease have shown benef...

Full description

Bibliographic Details
Main Authors: Jonas E. Svensson, Martin Bolin, Daniel Thor, Pete A. Williams, Rune Brautaset, Marcus Carlsson, Peder Sörensson, David Marlevi, Rubens Spin-Neto, Monika Probst, Göran Hagman, Anton Forsberg Morén, Miia Kivipelto, Pontus Plavén-Sigray
Format: Article
Language:English
Published: BMC 2024-04-01
Series:BMC Neurology
Subjects:
Rapamycin
Sirolimus
Alzheimer’s disease
Clinical trial
PET
MRI
Online Access:https://doi.org/10.1186/s12883-024-03596-1

Internet

https://doi.org/10.1186/s12883-024-03596-1

Similar Items